GlaxoSmithKline London

GSK lifts long-term sales targets on new drug pipeline

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline.It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.

Reuters on MSN · 15h

GSK launches $2.5 billion buyback, lifts sales target after stellar Q4

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue.

The Wall Street Journal on MSN · 1d

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.

Bloomberg on MSN · 1d

GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.

The Financial Times · 1d

GSK launches £2bn buyback on strong HIV and cancer drugs sales

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.

Arizona says GlaxoSmithKline's greed endangered kids with asthma

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

1don MSN

FTSE 100 giant GSK eyes more than £40bn in sales by 2031

Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...

LONDON BRIEFING: GSK hails pipeline as ups 2031 sales target

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...

FiercePharma7h

Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

FTSE 100 movers: GSK surges on guidance; DCC in the red

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

LONDON MARKET MIDDAY: FTSE 100 edges up, gold gleams and GSK shines

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

pharmaphorum7d

Ex-GSK vaccine chief to lead new UK biotech Vicebio

GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...

London open: FTSE nudges up; GSK surges on guidance upgrade

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

European markets open mixed ahead of more earnings reports; GSK up 6%

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Macau Business1d

GSK sees annual profit slide on Zantac drug fallout

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results